Christopher M Jewell

Cartesian Therapeutics, Inc.

NIH Rank #4521
  • R01 Holder
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$2.2M
Fiscal year 2024
Grants Awarded
3
Active NIH grants
National Rank
#4,521
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $2.2M across 3 grants · National rank #4521.

Top grants by award amount

Christopher M Jewell's NIH grant portfolio, ranked by award amount.

  • 1R44NS137943-01R44
    Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)
    $1.5M
    award amount
  • 5R01AI169686-03R01
    Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots
    $554.7K
    award amount
  • 1U44AI184200-01U44
    Targeting BCMA+ Cells with RNA-engineered CAR T cells to treat Lupus: A Phase 2 clinical study
    $149K
    award amount

Affiliations

Institutions that have administered grants for Christopher M Jewell.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Cartesian Therapeutics, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #4521
  6. 2024
    Entered Top 25% Nationally
    Ranked #4521
  7. 2024
    Multi-Institutional Research
    Awards at 2 institutions